Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

Pérez Encinas, Manuel Mateo
Thumbnail
Estadísticas
Estadísticas
Identificadores
Identificadores
URI: http://hdl.handle.net/20.500.11940/2944
PMID: 25756742
ISSN: 2045-7634
Registro completo
Servicios
Servicios
RISMendeleyLinksolver
Fecha de publicación
2015
Tipo de contenido
Artigo